Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip
Status:
Completed
Trial end date:
2018-10-09
Target enrollment:
Participant gender:
Summary
This is an open-label study to compare systemic exposure to triamcinolone acetonide following
a dose of extended-release FX006 or immediate-release TAcs (triamcinolone acetonide
suspension) in patients with osteoarthritis of the shoulder (glenohumeral joint) or hip